Steris fined $1 mil. for failing to submit stability test failure reports to FDA.
Executive Summary
STERIS FINED $1 MIL. FOR FAILING TO SUBMIT STABILITY TEST FAILURE REPORTS TO FDA in Greenbelt, Md. federal court Feb. 5. Steris Laboratories signed a plea agreement in January with the U.S. government, pleading guilty to five counts of failing to submit field alerts and annual reports with FDA for two drugs, prochlorperazine and neomycin/polymyxin B/gramicidin ophthalmic solution. "On several occasions between 1992 and 1995...Steris failed to submit to FDA required field alert reports concerning stability test failures for the drugs," the plea agreement states. Federal Judge Deborah Chasanow sentenced Steris to the maximum fine for the offense.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth